vs
Side-by-side financial comparison of CRA INTERNATIONAL, INC. (CRAI) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
CRA INTERNATIONAL, INC. is the larger business by last-quarter revenue ($197.0M vs $185.2M, roughly 1.1× AMICUS THERAPEUTICS, INC.). CRA INTERNATIONAL, INC. runs the higher net margin — 6.7% vs 0.9%, a 5.8% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 11.6%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 7.1%).
CRA INTERNATIONAL, INC.CRAIEarnings & Financial Report
CRA International, Inc. is a global consulting firm headquartered in Boston. The firm provides expert testimony and litigation support, strategic advice, and analysis to law firms, corporations, accounting firms, and governments.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
CRAI vs FOLD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $197.0M | $185.2M |
| Net Profit | $13.2M | $1.7M |
| Gross Margin | — | 85.7% |
| Operating Margin | 10.5% | 8.6% |
| Net Margin | 6.7% | 0.9% |
| Revenue YoY | 11.6% | 23.7% |
| Net Profit YoY | -12.0% | -88.5% |
| EPS (diluted) | $1.99 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $197.0M | $185.2M | ||
| Q3 25 | $185.9M | $169.1M | ||
| Q2 25 | $186.9M | $154.7M | ||
| Q1 25 | $181.9M | $125.2M | ||
| Q4 24 | $176.4M | $149.7M | ||
| Q3 24 | $167.7M | $141.5M | ||
| Q2 24 | $171.4M | $126.7M | ||
| Q1 24 | $171.8M | $110.4M |
| Q4 25 | $13.2M | $1.7M | ||
| Q3 25 | $11.5M | $17.3M | ||
| Q2 25 | $12.1M | $-24.4M | ||
| Q1 25 | $18.0M | $-21.7M | ||
| Q4 24 | $15.0M | $14.7M | ||
| Q3 24 | $11.4M | $-6.7M | ||
| Q2 24 | $6.5M | $-15.7M | ||
| Q1 24 | $13.7M | $-48.4M |
| Q4 25 | — | 85.7% | ||
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 90.2% | ||
| Q1 25 | — | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | — | 90.6% | ||
| Q2 24 | — | 91.1% | ||
| Q1 24 | — | 87.7% |
| Q4 25 | 10.5% | 8.6% | ||
| Q3 25 | 9.3% | 20.3% | ||
| Q2 25 | 10.6% | -6.1% | ||
| Q1 25 | 14.0% | -6.3% | ||
| Q4 24 | 12.2% | 10.7% | ||
| Q3 24 | 11.0% | 15.3% | ||
| Q2 24 | 6.6% | 11.8% | ||
| Q1 24 | 11.4% | -25.1% |
| Q4 25 | 6.7% | 0.9% | ||
| Q3 25 | 6.2% | 10.2% | ||
| Q2 25 | 6.5% | -15.8% | ||
| Q1 25 | 9.9% | -17.3% | ||
| Q4 24 | 8.5% | 9.8% | ||
| Q3 24 | 6.8% | -4.8% | ||
| Q2 24 | 3.8% | -12.4% | ||
| Q1 24 | 8.0% | -43.9% |
| Q4 25 | $1.99 | $0.00 | ||
| Q3 25 | — | $0.06 | ||
| Q2 25 | — | $-0.08 | ||
| Q1 25 | — | $-0.07 | ||
| Q4 24 | — | $0.05 | ||
| Q3 24 | — | $-0.02 | ||
| Q2 24 | — | $-0.05 | ||
| Q1 24 | — | $-0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.2M | $293.5M |
| Total DebtLower is stronger | — | $392.7M |
| Stockholders' EquityBook value | $213.6M | $274.2M |
| Total Assets | $628.9M | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | $293.5M | ||
| Q3 25 | $22.5M | $263.8M | ||
| Q2 25 | $19.4M | $231.0M | ||
| Q1 25 | $25.6M | $250.6M | ||
| Q4 24 | $26.7M | $249.9M | ||
| Q3 24 | $24.5M | $249.8M | ||
| Q2 24 | $24.6M | $260.1M | ||
| Q1 24 | $37.1M | $239.6M |
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M | ||
| Q1 24 | — | $388.4M |
| Q4 25 | $213.6M | $274.2M | ||
| Q3 25 | $201.7M | $230.4M | ||
| Q2 25 | $197.0M | $204.3M | ||
| Q1 25 | $227.3M | $193.6M | ||
| Q4 24 | $212.1M | $194.0M | ||
| Q3 24 | $204.5M | $178.8M | ||
| Q2 24 | $191.7M | $132.5M | ||
| Q1 24 | $211.8M | $130.7M |
| Q4 25 | $628.9M | $949.9M | ||
| Q3 25 | $629.0M | $868.8M | ||
| Q2 25 | $606.8M | $815.3M | ||
| Q1 25 | $590.4M | $789.8M | ||
| Q4 24 | $571.4M | $785.0M | ||
| Q3 24 | $582.3M | $786.6M | ||
| Q2 24 | $546.0M | $749.5M | ||
| Q1 24 | $552.5M | $721.8M |
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× | ||
| Q1 24 | — | 2.97× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $22.4M | $16.3M |
| Free Cash FlowOCF − Capex | — | $16.0M |
| FCF MarginFCF / Revenue | — | 8.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 1.70× | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.4M | $16.3M | ||
| Q3 25 | $36.5M | $35.7M | ||
| Q2 25 | $5.9M | $-26.5M | ||
| Q1 25 | $-80.0M | $7.8M | ||
| Q4 24 | $79.4M | $-3.9M | ||
| Q3 24 | $31.6M | $-23.0M | ||
| Q2 24 | $1.8M | $22.7M | ||
| Q1 24 | $-63.1M | $-29.7M |
| Q4 25 | — | $16.0M | ||
| Q3 25 | $35.9M | $35.3M | ||
| Q2 25 | $4.7M | $-28.9M | ||
| Q1 25 | $-81.0M | $7.5M | ||
| Q4 24 | $68.8M | $-4.2M | ||
| Q3 24 | $28.6M | $-23.3M | ||
| Q2 24 | $-509.0K | $21.6M | ||
| Q1 24 | $-63.8M | $-31.5M |
| Q4 25 | — | 8.6% | ||
| Q3 25 | 19.3% | 20.9% | ||
| Q2 25 | 2.5% | -18.7% | ||
| Q1 25 | -44.5% | 6.0% | ||
| Q4 24 | 39.0% | -2.8% | ||
| Q3 24 | 17.0% | -16.5% | ||
| Q2 24 | -0.3% | 17.0% | ||
| Q1 24 | -37.1% | -28.5% |
| Q4 25 | — | 0.2% | ||
| Q3 25 | 0.3% | 0.2% | ||
| Q2 25 | 0.6% | 1.6% | ||
| Q1 25 | 0.5% | 0.2% | ||
| Q4 24 | 6.0% | 0.2% | ||
| Q3 24 | 1.8% | 0.3% | ||
| Q2 24 | 1.4% | 0.9% | ||
| Q1 24 | 0.4% | 1.6% |
| Q4 25 | 1.70× | 9.62× | ||
| Q3 25 | 3.19× | 2.06× | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | -4.44× | — | ||
| Q4 24 | 5.30× | -0.27× | ||
| Q3 24 | 2.76× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | -4.61× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRAI
Segment breakdown not available.
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
